AP
The startup develops unmodified and genetically-modified natural killer (NK) cell therapies to target hematologic cancers and viral infections. By providing allogeneic NK cell therapy and antibodies, the company enhances patients' innate immune response, offering a critical defense against these diseases.
Updated 4 months ago
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops unmodified and genetically-modified natural killer (NK) cell therapies to target hematologic cancers and viral infections. By providing allogeneic NK cell therapy and antibodies, the company enhances patients' innate immune response, offering a critical defense against these diseases.